Status:
COMPLETED
Ciclosporin in HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)
Lead Sponsor:
Imperial College London
Collaborating Sponsors:
Medical Research Council
University Hospital Birmingham
Conditions:
HTLV I Associated Myelopathy
Eligibility:
All Genders
16-75 years
Phase:
PHASE2
PHASE3
Brief Summary
HAM/TSP is a chronic disease of the spinal cord, caused by a virus called HTLV-I. Worldwide approximately 20 million persons are infected.Infection with HTLV-I is lifelong, and about 3% of infected pe...
Detailed Description
This is a proof of concept, open, observational study of Ciclosporin for the treatment of HTLV-I-associated myelopathy in patients with less than 2 years disease or new evidence of progression. After ...
Eligibility Criteria
Inclusion
- Early (less than 2 years) HAM
- Progressing (within past 3 months) HAM
- Important to study the effect of therapy on disease that is most active as most likely to detect and measure improvement
Exclusion
- HIV infection
- Tuberculosis, strongyloidiasis or other infection related to immune compromise
- Hepatitis B \& C viral infections
- Malignancy
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT00773292
Start Date
August 1 2006
End Date
January 1 2010
Last Update
September 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Centre for Human Retrovirology
London, United Kingdom, W2 1NY